The abstract is read at the publisher; the summary is JClub's.
LGsig, a gene-expression classifier for diffuse large B-cell lymphoma, uses 294 genes to assign all cases into LymphGen-like subtypes and improves prediction of pola-R-CHP benefit.
- Why it matters: Existing LymphGen tools are limited by incomplete classification and lack nongenetic biology that can shape therapeutic response in DLBCL.
- What they did: Built from paired genomic and transcriptomic data (N = 764) across MYD88 L265P/CD79B, BCL6/NOTCH2, EZH2/BCL2, and SGK1/TET2 mutation-defined groups, LGsig was tested on POLARIX RNAseq (N = 678).
- The result: In POLARIX, LGsig outperformed LymphGen as a biomarker by identifying DLBCL subtypes with survival benefit from pola-R-CHP versus R-CHOP in both LymphGen-classified and LymphGen-unclassified cases.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.